Obesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared Holz

February 1, 2024
Obesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared HolzObesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared Holz

Jared Holz, Mizuho Securities, joins ‘Fast Money’ to talk demand in the obesity drug space and who is benefiting from the supply-demand imbalance.

Share This

Latest Mizuho News

See all news
Selective opportunities in software stocks amid sell-off, says Mizuho’s Gregg Moskowitz

Selective opportunities in software stocks amid sell-off, says Mizuho’s Gregg Moskowitz

February 17, 2026
Eli Lilly has already won the weight loss drug battle, says Mizuho’s Jared Holz

Eli Lilly has already won the weight loss drug battle, says Mizuho’s Jared Holz

February 23, 2026
Polymarket settling with USDC helped drive our upgrade of Circle, says Mizuho’s Dan Dolev

Polymarket settling with USDC helped drive our upgrade of Circle, says Mizuho’s Dan Dolev

February 25, 2026

Mizuho news from around the globe

 Mizuho Global News
back-to-top-blue